Search
Dexmethylphenidate
go.drugbank.com/drugs/DB06701ApprovedInvestigationalThe d-isomer is thought to have greater effect with fewer side effects than the l-isomer or the racemic mixture[A177181]. … Dexmethylphenidate is the dextrorotary form of methylphenidate introduced in 2002[A177181]. It is a norepinephrine-dopamine reuptake inhibitor (NDRI) and thus a psychostimulant[A177193].
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeEpoprostenol
go.drugbank.com/drugs/DB01240ApprovedInvestigationalThe sodium salt has been also used to treat primary pulmonary hypertension.
Products: Estenol 0,5 mg İnfüzyonluk Çözelti Hazırlamak İçin Toz ve Çözücü, 1 ADET, Estenol 1,5 mg İnfüzyonluk Çözelti Hazırlamak İçin Toz ve Çözücü, 1 ADETPhenindamine
go.drugbank.com/drugs/DB01619ApprovedAntihistamines such as phenindamine appear to compete with histamine for histamine H1- receptor sites on effector cells. … The antihistamines antagonize those pharmacological effects of histamine which are mediated through activation of H1- receptor sites and thereby reduce the intensity of allergic reactions and tissue injury
Vutrisiran
go.drugbank.com/drugs/DB16699ApprovedInvestigational[A249010] TTR mutations lead to the formation of misfolded TTR proteins, which form amyloid fibrils that deposit in different types of tissues. … [A249010] The Val30Met variant is the most prevalent among hereditary ATTR patients with polyneuropathy, especially in Portugal, France, Sweden, and Japan.
Oxymetholone
go.drugbank.com/drugs/DB06412ApprovedIllicitThe uncontrolled misuse of oxymetholone can lead to a large variety of detrimental effects, the most often reported of which are cardiovascular events. … Oxymetholone is a synthetic anabolic steroid marketed under the brand name Anapolon by Hoffmann La Roche Limitedand used in the treatment of osteoporosis, anaemia, and as an agent to stimulate muscle growth
Sarilumab
go.drugbank.com/drugs/DB11767ApprovedInvestigationalSarilumab is a fully human anti-interleukin 6 (IL-6) receptor monoclonal IgG1 antibody that binds to both membrane-bound and soluble IL-6 receptor forms, thus blocking the cis- and trans-inflammatory signalling … [A27262] Sarilumab was developed by Sanofi and Regeneron Pharmaceuticals, Inc; it was US FDA-approved in May 2017 and followed by EU approval in June 2017 for the treatment of moderate to severe rheumatoid
Categories: Interleukin-6 Receptor AntagonistBromotheophylline
go.drugbank.com/drugs/DB14018Approved[L1082] It is also approved by Health Canada to be used alone or in combination with [DB00316] in OTC products.[L1113] … From this mixture, bromotheophylline acts as a weak diuretic that has been used along with some analgesics to relieve the symptoms of premenstrual syndrome.
Abrocitinib
go.drugbank.com/drugs/DB14973ApprovedInvestigational[A244549] Abrocitinib was approved by the European Commission on December 10, 2021, for the treatment of moderate-to-severe atopic dermatitis (AD) in adults who are candidates for systemic therapy. … [L39784] On January 14, 2022, the FDA approved abrocitinib for the treatment of refractory, moderate-to-severe AD in adults whose disease is not adequately controlled with other systemic drug products,
Ozanimod
go.drugbank.com/drugs/DB12612ApprovedInvestigationalOzanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. … [L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020.
Categories: Sphingosine 1-phosphate Receptor Modulator, Sphingosine 1 Phosphate Receptor ModulatorsFloxuridine
go.drugbank.com/drugs/DB00322ApprovedInvestigationalIt has been used to treat hepatic metastases of gastrointestinal adenocarcinomas and for palliation in malignant neoplasms of the liver and gastrointestinal tract. … When administered by slow, continuous, intra-arterial infusion, it is converted to floxuridine monophosphate.